22234 Federal Register / Vol. 66, No. 86 / Thursday, May 3, 2001 / Notices

the relationship between diet, nutrition

and health in a representative sample of

the United States. NHANES monitors

the prevalence of chronic conditions

and risk factors related to health such as

coronary heart disease, arthritis,

osteoporosis, pulmonary and infectious

diseases, diabetes, high blood pressure,

high cholesterol, obesity, smoking, drug

and alcohol use, environmental

exposures, and diet.

NHANES data are used to establish

the norms for the general population

against which health care providers can

compare such patient characteristics as

height, weight, and nutrient levels in

the blood. Data from NHANES can be

compared to those from previous

surveys to monitor changes in the health

of the U.S. population. NHANES will

also establish a national probability

sample of genetic material for future

genetic research for susceptibility to

disease.

Users of NHANES data include

Congress; the World Health

Organization; Federal agencies such as

NIH, EPA, and USDA; private groups

such as the American Heart Association;

schools of public health; private

businesses; individual practitioners; and

administrators. NHANES data are used

to establish, monitor, and evaluate

recommended dietary allowances, food

fortification policies, programs to limit

environmental exposures, immunization

guidelines and health education and

disease prevention programs. The

current submission requests approval

through November 2004.

The survey description, contents, and

uses are the same as those in the

previous Federal Register notice for this

survey which was published on March

27, 2000 (Volume 65, Number 59).

There is no net cost to respondents

other than their time. Respondents are

reimbursed for any out-of-pocket costs

such as transportation to and from the

examination center.

Category

Number of

respondents

per year

Number of

responses/

respondent

Avg. burden

per response

(in hours)

Total burden

(hours)

1. Screening interview only ............................................................................. 13,333 1 0.167 2,227

2. Screener and family interviews only ............................................................ 500 1 0.434 217

3. Screener, family, and SP interviews only .................................................... 882 1 1.101 971

4. Screener, family, and SP interviews and primary MEC exam only ............ 4,951 1 6.669 33,018

5. Screener, household, and SP interviews, primary MEC exam and full

MEC replicate exam ..................................................................................... 248 1 11.669 2,894

6. Screener, household, and SP interviews, and home exam ........................ 50 1 1.851 93

7. Quality control verification ........................................................................... 1,333 1 0.030 40

8. Special studies ............................................................................................ 2,067 1 0.500 1,034

Total .......................................................................................................... 40,493

Dated: April 27, 2001.

Nancy Cheal,

Acting Associate Director for Policy, Planning

and Evaluation, Centers for Disease Control

and Prevention.

[FR Doc. 01–11066 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 02002]

Grants for Rape Prevention and

Education

AGENCY: Centers for Disease Control and

Prevention (CDC), Department of Health

and Human Services (DHHS).

ACTION: Notice of the availability of

fiscal year 2002 funds and request for

comments.

SUMMARY: The Centers for Disease

Control and Prevention (CDC)

announces the availability of fiscal year

(FY) 2002 funds for targeted grants to

state health departments to support

programs addressing violence against

women. The Rape Prevention and

Education Grant Program strengthens

education and training to combat

violence against women by supporting

increased awareness, education and

training, and the operation of hotlines.

CDC will award targeted grants to State

Health Departments to be used for rape

prevention and education programs

conducted by rape crisis centers, State

sexual assault coalitions, and other

public and private nonprofit entities.

Assistance will be provided only to

the health departments of States or their

bona fide agents who are current

recipients of Rape Prevention and

Education funding, including: the

District of Columbia, the

Commonwealth of Puerto Rico, the

Virgin Islands, the Commonwealth of

the Northern Mariana Islands, American

Samoa, Guam, the Federated States of

Micronesia, the Republic of the

Marshall Islands, and the Republic of

Palau. Approximately $42,000,000 is

available in FY 2002, for funding under

this formula-based grant program.

It is expected that the awards will

begin on or about October 1, 2001, and

will be made for a 12-month budget

period within a project period of up to

five years. Continuation awards will be

made within the project period based on

satisfactory progress reflected in the

annual continuation application.

States must adhere to Congressional

legislation regarding the allowable uses

for these funds. Not more than five

percent (exclusive of Direct Assistance)

of any grant or contract through the

grant may be obligated for

administrative costs. This five percent

limitation is in lieu of, and replaces, the

indirect cost rate. Targeted grants to

States are to be used for rape prevention

and education programs conducted by

rape crisis centers, State sexual assault

coalitions, and other public and private

nonprofit entities for: educational

seminars; the operation of hotlines;

training programs for professionals; the

preparation of informational material;

education and training programs for

students and campus personnel

designed to reduce the incidence of

sexual assault at colleges and

universities; education to increase

awareness about drugs used to facilitate

rapes or sexual assault; and other efforts

to increase awareness of the facts about

or to help prevent sexual assault,

including efforts to increase awareness

in underserved communities and

awareness among individuals with

disabilities (as defined in section 3 of

the Americans with Disabilities Act of

1990 (42 U.S.C. 12102)).

A State may not use more than two

percent of the amount received for each

fiscal year for surveillance studies or

prevalence studies. Amounts provided

to States must be used to supplement,

and not supplant, other Federal, State,

and local public funds expended to

provide the services described above.

Grant funds cannot be used for

Federal Register / Vol. 66, No. 86 / Thursday, May 3, 2001 / Notices 22235

construction, renovation, the lease of

passenger vehicles, the development of

major software applications, or

supplanting current applicant

expenditures.

The National Center for Injury

Prevention and Control of CDC will

provide information on submitting

applications via the Rape Prevention

and Education Version of the Grant

Application and Reporting System

(RPE–GARS).

DATES: Awards will begin on or about

October 1, 2001, and will be made for

a 12-month budget period within a

project period of up to five years.

Comments are due June 4, 2001.

ADDRESSES: Interested persons are

invited to comment on the proposed

program. All comments received on or

before June 4, 2001 will be considered

before the final program announcement

is published. Address comments to:

Wendy Watkins, Division of Violence

Prevention, National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention (CDC),

4770 Buford Highway, NE, Mailstop K–

58, Atlanta, GA 30341–3724, Telephone

(770) 488–1567, Internet address:

dmw7@cdc.gov.

FOR FURTHER INFORMATION CONTACT:

Wendy Watkins, Division of Violence

Prevention, National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention (CDC),

4770 Buford Highway, NE, Mailstop K–

58, Atlanta, GA 30341–3724, Telephone

(770) 488–1567, Internet address:

dmw7@cdc.gov.

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and

Operations,, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–11068 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Request for Input on Vaccine

Financing

AGENCY: Centers for Disease Control and

Prevention (CDC), Department of Health

and Human Services (DHHS).

ACTION: Notice and request for public

comment.

SUMMARY: The National Vaccine

Advisory Committee (NVAC) Work

Group on the Introduction of New

Vaccines seeks input on issues that may

be barriers to the optimal

implementation of new vaccines. The

work group is evaluating how vaccine

financing affects the standard of care for

different population subgroups.

Vaccine financing can impact specific

population subgroups differentially in

terms of access and supply of new

vaccines. The process by which the

public and private sector purchase and

distribute vaccines may differ in

important ways. The public sector plays

a major role in the financing of pediatric

vaccine, but it plays a smaller role in the

financing of adult vaccines. The timing

of public purchase may depend on

specific advisory group

recommendations as well as specific

state budgets. The eligibility for public

and private payer programs may also

vary.

We are asking partner organizations

and groups to submit their items on the

pluses and minuses of the current

vaccine financing system. In addition to

identifying potential barriers to the

optimal implementation of vaccines due

to vaccine financing, possible solutions

to these problems are requested. The

information gathered from the partners

will be used as the basis for a meeting

to develop options for the NVAC to

consider.

DATES: Comments and information must

be submitted by May 31, 2001.

ADDRESSES: Comments and information

regarding Vaccine Financing should be

submitted to the National Vaccine

Program Office, Attn: Introduction of

New Vaccines, Centers for Disease

Control and Prevention, Mailstop D–66,

1600 Clifton Road, NE., Atlanta, Georgia

30333; Federal Express Address: 200 E.

Ponce de Leon Avenue, Decatur,

Georgia 30030; fax: 404–687–6687; email: nvpo@cdc.gov.

FOR FURTHER INFORMATION CONTACT: The

National Vaccine Program Office, Attn:

Introduction of New Vaccines, Centers

for Disease Control and Prevention,

Mailstop D–66, 1600 Clifton Road, NE.,

Atlanta, Georgia 30333; Federal Express

Address: 200 E. Ponce de Leon Avenue,

Decatur, Georgia 30030; fax: 404–687–

6687; e-mail: nvpo@cdc.gov.

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and

Operations, Centers for Disease Control and

Prevention.

[FR Doc. 01–11067 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N–0183]

Elanco Animal Health, A Div. of Eli Lilly

& Co. et al.; Withdrawal of Approval of

NADAs

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 13 new animal drug

applications (NADAs) listed below at

the request of the sponsor. In a final rule

published elsewhere in this issue of the

Federal Register, FDA is amending the

animal drug regulations by removing the

portions reflecting approval of the

NADAs.

DATES: Withdrawal of approval is

effective May 14, 2001.

FOR FURTHER INFORMATION CONTACT:

Pamela K. Esposito, Center for

Veterinary Medicine (HFV–210), Food

and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 301–827–

5593.

SUPPLEMENTARY INFORMATION: The

following sponsors have requested that

FDA withdraw approval of the NADAs

listed below because the products are no

longer manufactured or marketed:

Sponsor NADA Number Product (Drug) 21 CFR Cite Affected

(Sponsor Drug Labeler Code)

Elanco Animal Health, A Div. of Eli Lilly & Co.,

Lilly Corporate Center, Indianapolis, IN 46285.

NADA 12–585 Tylan Injectable (tylosin tartrate).522.2640b (000986)

............................................................................. NADA 15–207 Hyferdex Injection (iron

dextran complex).

522.1183(c) (000986)